Find more information about Teva in your location, or contact a local representative on our local sites
North America
International Markets
North America
Toggle North America
International Markets
Toggle International Markets
Europe
Toggle Europe
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis
- Study Title
- Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- Teva Identifier
- ALS-TAL-201-OL
- ClinicalTrials.gov Identifier
- NCT00982150
- Study Status
- Terminated
- Trial Condition(s)
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Talampanel
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age Range
- 18 Years to 80 Years
- Trial Duration
- 09/01/2009 - 06/01/2010
- Phase
- Phase 2
